Drugs / gp100:209-217
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00080353 | Mar 2004 → Dec 2007 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00019396 | Feb 1998 → Mar 2007 | melanoma, renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp100:209-217 | “Patients may receive melanoma peptide immunization comprised of MART-1 immunodominant peptide, gp100:209-217, gp100:280-288, and tyrosinase peptide emulsified in Montanide...” NCT00019396 ↗ |
| Modality | Peptide | “Patients may receive melanoma peptide immunization comprised of MART-1 immunodominant peptide, gp100:209-217, gp100:280-288, and tyrosinase peptide emulsified in Montanide...” NCT00019396 ↗ |
| Route | Subcutaneous | “Patients may receive melanoma peptide immunization comprised of MART-1 immunodominant peptide, gp100:209-217, gp100:280-288, and tyrosinase peptide emulsified in Montanide...” NCT00019396 ↗ |